Page 4 - Peter Wilden News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peter wilden. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peter Wilden Today - Breaking & Trending Today

PolyPeptide publishes invitation to the annual General Meeting 2022

PolyPeptide Group / Key word(s): AGMEGM01.04.2022 / 07:00 PolyPeptide publishes invitation to the annual General Meeting 2022Zug, 1 April 2022 - PolyPeptide Group AG (PolyPeptide), a global leader in peptide custom development and manufacturing, published today the invitation to its first annual General Meeting whic. ....

Philippe Weber , Peter Wilden , Head Of Investor Relations Corporate Communications , Swiss Exchange , Contract Development Manufacturing Organization , Nomination Committee , Polypeptide Group Key , Polypeptide Group , Polypeptide Group Ag , Company Articles Of Association , General Meeting , Peptide Group , Investor Relations , Contract Development , Manufacturing Organization ,

PolyPeptide Group prices IPO at CHF 64.00 per share and starts trading on the Swiss Stock Exchange


 
About PolyPeptide Group
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide s shares (SIX: PPGN) are listed on the Swiss Stock Exchange. For more information, visit polypeptide.com. ....

United States , District Of Columbia , United Kingdom , Morgan Stanley Europe , Peter Wilden , Morgan Stanley , Head Of Investor Relations Corporate Communications , Gossler Co , Lemongrass Communications , Contract Development Manufacturing Organization , Swiss Exchange At Credit Suisse , Draupnir Holding , Merrill Lynch International , Danske Bank , European Union Withdrawal , European Union , Commission Delegated Directive , Polypeptide Group Ag , Rothschild Co , Swiss Stock Exchange , Credit Suisse , Financial Services , International Reporting Standard , Swiss Financial Services , Polypeptide Group , Peptide Group ,

International PolyPeptide Group Chooses SIX For Its IPO


International PolyPeptide Group Chooses SIX For Its IPO
Date
29/04/2021
Today, PolyPeptide Group AG (Ticker PPGN ), a global leader in peptide development and manufacturing, listed its shares on the Swiss Stock Exchange. The opening price was CHF 72.50 per share, resulting in a market capitalization of CHF 2.4 billion.
With PolyPeptide Group, SIX welcomes another company from the life sciences sector, further expanding its strong peer group and strengthening its position as Europe’s leading exchange for life sciences companies.
The issued share capital of PolyPeptide comprises of 33,125,001 registered shares, whereas 3,125,000 newly issued registered shares together with existing 8,396,740 registered shares were offered in the IPO. At an issue price of CHF 64.00 per registered share, the placement volume was CHF 737 million (excluding over-allotment option). In addition, the selling shareholder has granted an overallotment option of up to 1,728,261 exis ....

Jos Dijsselhof , Peter Wilden , Swiss Stock Exchange , Polypeptide Group , Polypeptide Group Ag Ticker , Swiss Stock , Chairman Polypeptide , சுவிஸ் ஸ்டாக் பரிமாற்றம் , சுவிஸ் ஸ்டாக் ,